Zomedica Non Current Assets Total from 2010 to 2024
| ZOM Stock | USD 0.13 0.0002 0.15% |
Non Current Assets Total | First Reported 2013-03-31 | Previous Quarter 153.3 M | Current Value 153.3 M | Quarterly Volatility 62.2 M |
Check Zomedica Pharmaceuticals financial statements over time to gain insight into future company performance. You can evaluate financial statements to find patterns among Zomedica main balance sheet or income statement drivers, such as Interest Expense of 183.8 K, Selling General Administrative of 30.5 M or Other Operating Expenses of 59.6 M, as well as many exotic indicators such as Price To Sales Ratio of 7.4, Dividend Yield of 0.0 or PTB Ratio of 0.78. Zomedica financial statements analysis is a perfect complement when working with Zomedica Pharmaceuticals Valuation or Volatility modules.
Zomedica | Non Current Assets Total |
Latest Zomedica Pharmaceuticals' Non Current Assets Total Growth Pattern
Below is the plot of the Non Current Assets Total of Zomedica Pharmaceuticals Corp over the last few years. It is the total value of a company's long-term assets, which are not expected to be converted into cash or used up within one year or the operating cycle, including property, plant, and equipment, and intangible assets. Zomedica Pharmaceuticals' Non Current Assets Total historical data analysis aims to capture in quantitative terms the overall pattern of either growth or decline in Zomedica Pharmaceuticals' overall financial position and show how it may be relating to other accounts over time.
| Non Current Assets Total | 10 Years Trend |
|
Non Current Assets Total |
| Timeline |
Zomedica Non Current Assets Total Regression Statistics
| Arithmetic Mean | 37,453,966 | |
| Geometric Mean | 1,695,054 | |
| Coefficient Of Variation | 173.58 | |
| Mean Deviation | 53,410,756 | |
| Median | 1,297,346 | |
| Standard Deviation | 65,011,679 | |
| Sample Variance | 4226.5T | |
| Range | 161M | |
| R-Value | 0.78 | |
| Mean Square Error | 1810.8T | |
| R-Squared | 0.60 | |
| Significance | 0.0007 | |
| Slope | 11,280,591 | |
| Total Sum of Squares | 59171.3T |
Zomedica Non Current Assets Total History
About Zomedica Pharmaceuticals Financial Statements
There are typically three primary documents that fall into the category of financial statements. These documents include Zomedica Pharmaceuticals income statement, its balance sheet, and the statement of cash flows. Zomedica Pharmaceuticals investors use historical funamental indicators, such as Zomedica Pharmaceuticals's Non Current Assets Total, to determine how well the company is positioned to perform in the future. Although Zomedica Pharmaceuticals investors may use each financial statement separately, they are all related. The changes in Zomedica Pharmaceuticals's assets and liabilities, for example, are also reflected in the revenues and expenses that we see on Zomedica Pharmaceuticals's income statement, which results in the company's gains or losses. Cash flows can provide more information regarding cash listed on a balance sheet, but not equivalent to net income shown on the income statement. We offer a historical overview of the basic patterns found on Zomedica Pharmaceuticals Financial Statements. Understanding these patterns can help to make the right decision on long term investment in Zomedica Pharmaceuticals. Please read more on our technical analysis and fundamental analysis pages.
| Last Reported | Projected for Next Year | ||
| Non Current Assets Total | 153.3 M | 161 M |
Also Currently Popular
Analyzing currently trending equities could be an opportunity to develop a better portfolio based on different market momentums that they can trigger. Utilizing the top trending stocks is also useful when creating a market-neutral strategy or pair trading technique involving a short or a long position in a currently trending equity.When determining whether Zomedica Pharmaceuticals is a strong investment it is important to analyze Zomedica Pharmaceuticals' competitive position within its industry, examining market share, product or service uniqueness, and competitive advantages. Beyond financials and market position, potential investors should also consider broader economic conditions, industry trends, and any regulatory or geopolitical factors that may impact Zomedica Pharmaceuticals' future performance. For an informed investment choice regarding Zomedica Stock, refer to the following important reports:Check out the analysis of Zomedica Pharmaceuticals Correlation against competitors. You can also try the Price Transformation module to use Price Transformation models to analyze the depth of different equity instruments across global markets.
Complementary Tools for Zomedica Stock analysis
When running Zomedica Pharmaceuticals' price analysis, check to measure Zomedica Pharmaceuticals' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Zomedica Pharmaceuticals is operating at the current time. Most of Zomedica Pharmaceuticals' value examination focuses on studying past and present price action to predict the probability of Zomedica Pharmaceuticals' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Zomedica Pharmaceuticals' price. Additionally, you may evaluate how the addition of Zomedica Pharmaceuticals to your portfolios can decrease your overall portfolio volatility.
| Portfolio Anywhere Track or share privately all of your investments from the convenience of any device | |
| Commodity Directory Find actively traded commodities issued by global exchanges | |
| FinTech Suite Use AI to screen and filter profitable investment opportunities | |
| Competition Analyzer Analyze and compare many basic indicators for a group of related or unrelated entities | |
| Money Managers Screen money managers from public funds and ETFs managed around the world | |
| Portfolio File Import Quickly import all of your third-party portfolios from your local drive in csv format |
Is Zomedica Pharmaceuticals' industry expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Zomedica Pharmaceuticals. If investors know Zomedica will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Zomedica Pharmaceuticals listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Earnings Share (0.04) | Revenue Per Share 0.026 | Quarterly Revenue Growth 0.192 | Return On Assets (0.07) | Return On Equity (0.14) |
The market value of Zomedica Pharmaceuticals is measured differently than its book value, which is the value of Zomedica that is recorded on the company's balance sheet. Investors also form their own opinion of Zomedica Pharmaceuticals' value that differs from its market value or its book value, called intrinsic value, which is Zomedica Pharmaceuticals' true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Zomedica Pharmaceuticals' market value can be influenced by many factors that don't directly affect Zomedica Pharmaceuticals' underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Zomedica Pharmaceuticals' value and its price as these two are different measures arrived at by different means. Investors typically determine if Zomedica Pharmaceuticals is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Zomedica Pharmaceuticals' price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.